Program
AZD8359
A development code.
Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Apr 8, 20261 company-led study, 1 open or runningNext primary completion: Nov 17, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Apr 8, 2026 | Apr 8, 2026 | Nov 17, 2027phase 2 · NCT07529717 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2026First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07529717 · 42 planned · United States, Australia, South Korea
Ahead
- Nov 17, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07529717
TargetBeta
STEAP2 →read by rule
“Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer”study text, by rule · the study
Other programs on STEAP2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| STEAP2-targeting Radioconjugate AZD2287rule | AstraZeneca | phase 2 | 2 |
| Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754 | AstraZeneca | phase 2 | 1 |
| Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516 | AstraZeneca | phase 2 | 1 |
| Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 | AstraZeneca | phase 2 | 1 |
| Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284 | AstraZeneca | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07529717Prostatic Neoplasms · United States, Australia, South Korea | 2 | Recruiting | Nov 17, 2027 | 42 |
How it is read
Names in the registry
- “AZD8359”, 4 entries
Codes read as this program: AZD8359.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.